ArticleCureus2026

Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity.

Masuho Saburi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.